Picture of Skinbiotherapeutics logo

SBTX Skinbiotherapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

REG - SkinBioTherapeutics - Positive Interim AxisBiotix Acne study results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240227:nRSa5861Ea&default-theme=true

RNS Number : 5861E  SkinBioTherapeutics PLC  27 February 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Positive interim data from consumer participant study for Acne

27 ​February 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that interim data from the AxisBiotix Acne food supplement consumer participant study with the lead formulation are very positive. The Company will continue the study to completion. The analysis and read-out of the final results is anticipated to occur before the end of Q1 2024.

 

The volunteer study, comprising 220 people, followed the same methodology to
the AxisBiotix-Ps study, with the supplement containing the lead formulation,
being supplied to participants in powder-form. Participants were then asked to
record scores against specific criteria on an app. The scoring criteria
included severity of acne, level of pain, attitude to appearance and levels of
confidence.

 

The full study length is 56 days to reflect the time it takes for the skin to
replenish itself completely. In people, the number of days ranges from 40-56
days, depending on age and location, therefore the maximum time was chosen for
the study.

 

Interim study results

 

 Criteria and questions                                                          Week 1              Week 5
 Severity of acne: How do you rate your spots on a scale of 1-10, with 10 being  71%                 37%
 the most severe
(score 4 or more)
(score 4 or more)
 Pain of acne spots: Are your spots painful? On a scale of 1 - 10, with 10       64%                 43%
 being the most concern
(score 4 or more)
(score 4 or more)
 Concern over appearance: How concerned are you about the effect your spots      94%                 56%
 have on your appearance? On a scale of 1 - 10, with 10 being the most concern
(score 4 or more)
(score 4 or more)
 Level of self-confidence: Do you worry about going out in public because of     84%                 47%
 your spots? On a scale of 1 - 10, with 10 being the most concern
(score 4 or more)
(score 4 or more)

 

While results at this interim point are positive, there can be no certainty
that these will either improve or be maintained.  The completion of the full
study and analysis of the total data set is required to understand the
outcomes.

 

The study is being conducted by an independent third-party, and the supplement
blend has been formulated and manufactured by the Dutch food supplement
provider Winclove Probiotics BV.

 

Stuart Ashman, CEO of SkinBioTherapeutics Plc, said:

 

"We are really excited to see such positive results against all the criteria
at this interim stage. After the success of running a consumer participant
study with the AxisBiotix-Ps product, we followed the same set-up for our acne
candidate. And, just like the AxisBiotix study, many participants have
recorded quite dramatic changes in their condition already. We have another
three weeks to go, but if the final results reflect similar levels of
effectiveness, we have the potential for a really important, new and effective
option for people with acne of all ages."

 

Up to 85% of people will suffer from acne at some point in their life and
sufferers tend to be keen to alleviate their symptoms. The global acne market
is worth $9.4billion with CAGR of 4.8% (Fortune Business Insights 2019). In
the UK alone, the market is worth c. £250m in 2022 and is projected to reach
c.£300m in 2030, with c.34% of adults in the UK experiencing acne at some
time in their lives. Acne is the most common skin condition and one of the top
10 most prevalent diseases worldwide.

 

Although not life-threatening, acne can cause irritation and life-long
scarring, and can negatively impact a person's mental health and self-esteem.
Acne develops when pores get clogged with dead skin, bacteria, and dried skin
oil buildup, which leads to redness, tenderness, pimples, nodules, or cysts
primarily on the face, back, or chest.

 

Acne can range from mild to severe and typically affects teenagers and young
adults but anyone can be affected. Treatment of severe acne often requires
topical steroid creams which can lead to undesirable side effects, including
skin dryness, irritation, and rashes. Alternative treatments include oral
medications where side effects can be more severe e.g. depression or suicidal
thoughts.

 

-Ends-

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

 

 For more information please contact:

SkinBioTherapeutics plc                            Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (financial press)              Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Jack Kincade                SkinBioTherapeutics@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQDLBLZLLZBBV

Recent news on Skinbiotherapeutics

See all news